4th Annual Cardio Symposium hosted by ACEA Biosciences

September 16, 2016
 | 
Hyatt Regency Vancouver

4Cardio_website_ftimage

Register for the 4th Annual Cardio Symposium, September 16-17, immediately prior to the 2016 SPS Meeting in Vancouver, Canada.

Cardiotoxicity and cardiac liability continues to be a major hurdle in drug development. Within the pharmaceutical industry, academic institutions, and regulatory agencies there are ongoing efforts to develop higher throughput and more predictive assays that can be used earlier in the drug discovery/development pipeline to minimize both cost and risk.

ACEA Biosciences’ annual Cardio Symposium is a forum to promote scientific exchange and collaboration amongst scientists working at the forefront of cardiac safety assessment and cardiovascular disease model research. Experts from both industry and academia will share their findings on combining human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes, cellular impedance, MEA and other technologies for cardiac safety assessment and cardiovascular disease studies.

Register Now!

Friday, September 16, 2016
4:30 PM – 6:00 PM Registration
6:00 PM – 9:00 PM Welcome Reception and Poster Session
Even # Poster Presentation (6:00 PM – 7:00 PM)
Odd # Poster Presentation (7:00 PM – 8:00 PM)
Saturday, September 17, 2016
7:30 AM – 8:20 AM Breakfast & Registration
8:20 AM – 8:50 AM Welcome and introduction yamaYama Abassi, Ph.D. (ACEA
Biosciences)
Session I: Cardiovascular Disease Models & Therapy
8:55 AM – 9:20 AM Measuring Clinical Cardiac Effect and Toxicity Jason_maynes_lrJason Maynes, M.D., Ph.D. (The Hospital for Sick Children, CANADA)
9:25 AM – 9:50 AM Human iPSC cardiomyocytes recapitulate bradycardia observed in patients treated with sphingosine-1-phosphate receptor agonists Hong_051816_044856_PMHong Shi, M.D. (Bristol-Myers
Squibb, USA)
9:55 AM – 10:20 AM Human Induced Pluripotent Stem Cells Capture Clinical Heterogeneity In Hearts of Cardiomyopathy Patients and Provide A Platform To Uncover Therapeutics Farah-Sheikh-cventFarah Sheikh, Ph.D., FCVS, FAHA (University of California, San Diego, USA)
10:25 AM – 10:55 AM Morning Break Session
Session II: Cardiac Safety Discovery
10:55 AM – 11:20AM Towards a Better Understanding of the Impedance Signal as an Indirect Measurement of Contractility in iCells/hIPSC-derived Cardiomyocytes MariaRomanMaria Roman, Ph.D. (Merck
Research Labs, USA)
11:25 AM – 11:50 AM Identify Biomarkers to Predict Tyrosine Kinase Inhibitors (TKIs) -Induced Cardiotoxicity Using iPSC- Derived Cardiomyocytes XiYangXi Yang, Ph.D. (Division of
Systems Biology/ National Center for Toxicological Research at FDA, USA)
11:55 AM – 12:20 PM Clinically relevant electrophysiological properties of human iPS cell-derived cardiomyocytes for the assessment of drug-induced Torsade de pointes risk SawadaKohei Sawada, Ph.D. (Eisai,
JAPAN)
12:25 PM – 1:30 PM Lunch & Networking (Group Photo @ 12:30 PM)
Session III: Cardiac Safety Assessment
1:30 PM –1:55 PM Human Stem Cell Derived Cardiomyocytes in Cardiac Safety Assessment BlinovaKsenia Blinova, Ph.D. (Food and Drug Administration, USA)
2:00 PM –2:25 PM Maturation of Human iPSC-cardiomyocytes in Long-term Culture for Cardiotoxicity Testing GuoLiang Guo, M.D., M.Sc. (FNLCR/NCI, USA)
2:30 PM –2:55 PM Evaluation of batch variations in induced pluripotent stem cell derived- human cardiomyocytes from two major suppliers MariaRomanLi Pang, M.D. (National Center for Toxicological Research at FDA, USA)
3:00 PM – 3:10 PM Developing high quality reagents, assays and platforms for predictive cardiac safety screening: validating stem cell-derived iPS cardiomyocytes on patch clamp and phenotypic platforms. RogersMarc Rogers, Ph.D. (Metrion Biosciences, UK)
3:15 PM – 3:30 PM Afternoon Break Session
3:30 PM – 3:55 PM Activity of Japan iPS Cardiac Safety Assessment (JiCSA) toward the new strategy of the Safety Pharmacology SekinoYuko Sekino, Ph.D. (National Institute of Health Sciences, JAPAN)
4:00 PM – 5:00 PM Panel Discussion- Cardio Safety Assessment using iPSC Cardiomyocyte and Future Regulatory Decision
5:00 PM Meeting Concludes

Click here to download the Agenda


Where:

Hyatt Regency Vancouver
655 Burrard St, Vancouver, BC V6C 2R7, Canada

Group rate: starts from 269 CAD. Book by September 1st, 2016 for group rates.

In order to book your guest room at the Hyatt Regency Vancouver, please click here for online reservations.